Clinton Names New NCI Director

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

WASHINGTON--President Clinton has appointed Dr. Richard D. Klausner as director of the National Cancer Institute. Dr. Klausner has served as chief, Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, since 1984. He earned his undergraduate degree at Yale and his MD from Duke.

WASHINGTON--President Clinton has appointed Dr. Richard D. Klausneras director of the National Cancer Institute. Dr. Klausner hasserved as chief, Cell Biology and Metabolism Branch, NationalInstitute of Child Health and Human Development, since 1984. Heearned his undergraduate degree at Yale and his MD from Duke.

In a statement of congratulations from the American Society ofClinical Oncology, John H. Glick, MD, president, called Dr. Klausnera "distinguished molecular biologist . . . with an impressiverecord of scientific and administrative accomplishments at theNIH."

Dr. Harold E. Varmus, NIH director, said that Dr. Klausner "bringsto this important post an extraordinary record of scientific achievement,admirable personal qualities, and a firm commitment to advancingthe nation's health through vigorous and innovative science. Iam sure that Dr. Klausner will provide the leadership that NIH'slargest and most visible institute needs as it carries forwardthe fight against cancer.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content